🇺🇸 FDA
Patent

US 8911733

Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions

granted A61KA61K2039/505A61P

Quick answer

US patent 8911733 (Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions) held by The Regents of the University of Colorado, a Body Corporate expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/505, A61P, A61P1/16, A61P11/00